Page 58 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Linklaters advises on HUTCHMED’s HK$4.17bn HKEX IPO Linklaters advised the joint sponsors and underwriters on the global offering and listing of HUTCHMED (China) Limited (HUTCHMED) on the main board of the Hong Kong Stock Exchange (Stock Code: 13). HUTCHMED, formerly known as Chi-Med (Hutchison China MediTech), is part of the multinational conglomerate CK Hutchison group. It is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. It is the first biotech company to bring a novel oncology drug from discovery through to unconditional approval and launch in China.

Hong kongCity ofUnited kingdomTiffany yanChristopher yipKevin cheungandchristopher yipChina limitedHong kong stock exchange codeLondon stock exchangeHong kong stock exchangeTechnology innovation boardShanghai stock exchange scienceStock codeHutchison china meditechAmerican depositary sharesNasdaq global select market